Project Grant R01CA296008
Award Date 8/14/25
Completion Date 7/31/29
Dollars Obligated $3.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This $997,410 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop non-invasive MRI-based techniques to detect and differentiate between the invasive neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes of high-grade glioma brain tumors. The project leverages recent discoveries about these tumor subtypes' distinct microstructural, metabolic, and synapse profiles to enable more comprehensive tumor...
- This Project Grant award of $687,279 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to uncover the effects of standard-of-care therapy on immune and neoplastic cell population dynamics in pre-clinical mouse models of glioblastoma (GBM) and analysis of human GBM samples. The goal is to identify tumor microenvironment areas of therapeutic...
- The National Institute of Neurological Disorders and Stroke (NINDS), through its Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded a $420,251 Project Grant to Brigham & Women's Hospital Inc. on May 6, 2025. The grant supports the development of an encapsulated cell-based oncolytic virus therapy for the treatment of glioblastoma (GBM), the most lethal primary brain tumor. The research aims to enhance the therapeutic efficacy of engineered...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $677,998 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Medical College of Wisconsin, Inc. (MCW). The project aims to externally validate and integrate radiopathomic models developed using autopsy and biopsy samples to better delineate the true extent of glioma tumors and identify microscopic infiltrating tumor cells. The research will refine...
- This federal Project Grant award of $677,801, provided by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research at Yale University to develop a non-invasive magnetic resonance imaging (MRI) technique called Deuterium Metabolic Imaging (DMI) for detecting and monitoring disease progression in patients with glioblastoma, an aggressive brain tumor. The key objectives are to: 1) validate the specificity of DMI for detecting active...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $229,078 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of North Carolina at Chapel Hill to investigate "Ferroptosis Sensitization in Glioblastoma". The project aims to leverage positron emission tomography (PET) imaging with the FSPG tracer to study the effects of dietary cysteine/methionine deprivation and radiation...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,820,337.00 to the Regents of the University of Michigan to develop new methods to directly measure metabolic pathway activity in mouse models and patients with glioblastomas (GBMs), which are deadly and incurable brain cancers. The goal is to identify optimal metabolic treatment strategies for GBM patients by evaluating the safety, on-target activity, and potential efficacy of new...
- This $194,022 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) supports research led by the Massachusetts General Hospital (MGH) to develop advanced deep learning models for predicting therapeutic response in cancer patients with brain metastases. The grant will fund the candidate, an oncologist at MGH, to build upon his expertise in...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research on targeted radioimmunotherapy for glioblastoma, a highly aggressive form of brain cancer. The $432,134 award was granted on June 5, 2025 to the University of Texas MD Anderson Cancer Center. The research aims to develop an innovative treatment approach using IL13RA2, a cell surface receptor expressed on glioblastoma tumors, as a target for delivering cytotoxic radioisotopes....
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...